Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 phase III maintenance study in ulcerative colitis remission
NL-OMON42465Phase 3Withdrawn
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing LT-02 add-on arm, Placebo add-on arm and Mesalamine comparator arm (3 arms). Primary endpoint: Relapse-free and not treatment failure at 48 weeks. Planned start May 2015; status: withdrawn.
02
Drugs
phosphatidylcholine (LT-02)Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON42465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42465.